Alzheimer's disease. Dementia in Alzheimer disease
Conditions
Interventions
Intervention 1: Intervention group: A capsule containing 750 mg of Olibuma resin is taken orally three times per day for 12 weeks. Capsules are provided by the Pharmacy Department of Herbal Drugs at I
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
55 Years to 82 Years
Inclusion criteria
Inclusion criteria: Patients with mild to moderate Alzheimer's disease based on the score of the MMSE test between 10-23
Exclusion criteria
Exclusion criteria: Diagnosis of Alzheimer's disease less than 6 months before entering the study Using cholinesterase inhibitors and / or memantine less than 90 days before entering the study or discontinuing them less than 90 days before entering the study Use of other drugs and substances such as ginkgo biloba or vitamin E that affect cognitive status less than 60 days before entering the study or discontinued less than 90 days before entering the study. Vascular dementia, thyroid disease, vitamin B12 deficiency, anemia, Lewy body dementia, liver function disorders, brain tumors, ischemic cerebrovascular accidents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive status. Timepoint: Study of cognitive status at the beginning of the study (before the intervention) and 12 weeks after the start of use of capsule containing Olibanum resin or placebo. Method of measurement: Using MMSE and CDR tests. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamid Reza Sadeghnia
Mashhad University of Medical Sciences
Outcome results
None listed